For miR-1246, it was shown that its expression was significantly decreased in B cells from SLE patients and that it specifically targeted the 3′-UTR of the early B cell factor 1 (EBF1) mRNA [125]. This evidence concerns the gene EBF1 and systemic lupus erythematosus.